243 related articles for article (PubMed ID: 17498708)
21. GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of elevated peak serum progesterone levels.
Orvieto R; Nahum R; Meltzer S; Liberty G; Anteby EY; Zohav E
Gynecol Endocrinol; 2013 Sep; 29(9):843-5. PubMed ID: 23802563
[TBL] [Abstract][Full Text] [Related]
22. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
[TBL] [Abstract][Full Text] [Related]
23. Letrozole and gonadotropins versus luteal estradiol and gonadotropin-releasing hormone antagonist protocol in women with a prior low response to ovarian stimulation.
Elassar A; Engmann L; Nulsen J; Benadiva C
Fertil Steril; 2011 Jun; 95(7):2330-4. PubMed ID: 21514582
[TBL] [Abstract][Full Text] [Related]
24. Accelerated endometrial maturation in the luteal phase of cycles utilizing controlled ovarian hyperstimulation: impact of gonadotropin-releasing hormone agonists versus antagonists.
Saadat P; Boostanfar R; Slater CC; Tourgeman DE; Stanczyk FZ; Paulson RJ
Fertil Steril; 2004 Jul; 82(1):167-71. PubMed ID: 15237007
[TBL] [Abstract][Full Text] [Related]
25. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.
Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B
Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489
[TBL] [Abstract][Full Text] [Related]
26. The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study.
Engmann L; DiLuigi A; Schmidt D; Benadiva C; Maier D; Nulsen J
Fertil Steril; 2008 Mar; 89(3):554-61. PubMed ID: 17678651
[TBL] [Abstract][Full Text] [Related]
27. Controlled ovarian hyperstimulation using multi-dose gonadotropin-releasing hormone (GnRH) antagonist results in less systemic inflammation than the GnRH-agonist long protocol.
Orvieto R; Volodarsky M; Hod E; Homburg R; Rabinson J; Zohav E; Anteby EY; Meltcer S
Gynecol Endocrinol; 2007; 23(8):494-6. PubMed ID: 17852411
[TBL] [Abstract][Full Text] [Related]
28. What is the preferred GnRH analogue for polycystic ovary syndrome patients undergoing controlled ovarian hyperstimulation for in vitro fertilization?
Orvieto R; Meltcer S; Homburg R; Nahum R; Rabinson J; Ashkenazi J
Fertil Steril; 2009 Apr; 91(4 Suppl):1466-8. PubMed ID: 18774558
[TBL] [Abstract][Full Text] [Related]
29. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.
Kolibianakis EM; Schultze-Mosgau A; Schroer A; van Steirteghem A; Devroey P; Diedrich K; Griesinger G
Hum Reprod; 2005 Oct; 20(10):2887-92. PubMed ID: 15979994
[TBL] [Abstract][Full Text] [Related]
30. Timing of human chorionic gonadotropin (hCG) hormone administration in IVF/ICSI protocols using GnRH agonist or antagonists: a systematic review and meta-analysis.
Chen Y; Zhang Y; Hu M; Liu X; Qi H
Gynecol Endocrinol; 2014 Jun; 30(6):431-7. PubMed ID: 24731070
[TBL] [Abstract][Full Text] [Related]
31. Can FSH co-trigger prevent OHSS?
Rosen MP; Meldrum DR
Fertil Steril; 2012 Mar; 97(3):534-5. PubMed ID: 22285746
[TBL] [Abstract][Full Text] [Related]
32. Mild/minimal stimulation for in vitro fertilization: an old idea that needs to be revisited.
Zarek SM; Muasher SJ
Fertil Steril; 2011 Jun; 95(8):2449-55. PubMed ID: 21550037
[TBL] [Abstract][Full Text] [Related]
33. Serum androgen levels in patients undergoing controlled ovarian hyperstimulation for in vitro fertilization cycles.
Orvieto R; Yulzari-Roll V; La Marca A; Ashkenazi J; Fisch B
Gynecol Endocrinol; 2005 Oct; 21(4):218-22. PubMed ID: 16316843
[TBL] [Abstract][Full Text] [Related]
34. Programming in vitro fertilization retrievals during working days after a gonadotropin-releasing hormone antagonist protocol with estrogen pretreatment: does the length of exposure to estradiol impact on controlled ovarian hyperstimulation outcomes?
Guivarc'h-Levêque A; Homer L; Arvis P; Broux PL; Moy L; Priou G; Vialard J; Colleu D; Dewailly D
Fertil Steril; 2011 Oct; 96(4):872-6. PubMed ID: 21868004
[TBL] [Abstract][Full Text] [Related]
35. Degrees of uncertainty--"statistically insignificant".
Claman P
Fertil Steril; 2008 Oct; 90(4):1331; author reply 1331. PubMed ID: 18793767
[No Abstract] [Full Text] [Related]
36. Luteal supplementation in in vitro fertilization: more questions than answers.
Hubayter ZR; Muasher SJ
Fertil Steril; 2008 Apr; 89(4):749-58. PubMed ID: 18406833
[TBL] [Abstract][Full Text] [Related]
37. GnRH agonist versus GnRH antagonist in controlled ovarian hyperstimulation: their role in patients with an unfavorable prognosis a priori.
Orvieto R; Homburg R; Meltcer S; Rabinson J; Anteby EY; Scharf S
Fertil Steril; 2009 Apr; 91(4 Suppl):1378-80. PubMed ID: 18675972
[TBL] [Abstract][Full Text] [Related]
38. [Onset and maintenance of the luteal phase with GnRH agonists or hCG in cycles under GnRH antagonists].
Olivennes F
J Gynecol Obstet Biol Reprod (Paris); 2004 Oct; 33(6 Pt 2):3S24-6. PubMed ID: 15643682
[TBL] [Abstract][Full Text] [Related]
39. Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm injection treatment cycle: impact on ovarian stimulation. A pilot study.
Blockeel C; Riva A; De Vos M; Haentjens P; Devroey P
Fertil Steril; 2011 Apr; 95(5):1714-9.e1-2. PubMed ID: 21300334
[TBL] [Abstract][Full Text] [Related]
40. Follitropin-alpha (Gonal-F) versus follitropin-beta (Puregon) in controlled ovarian hyperstimulation for in vitro fertilization: is there any difference?
Orvieto R; Nahum R; Rabinson J; Ashkenazi J; Anteby EY; Meltcer S
Fertil Steril; 2009 Apr; 91(4 Suppl):1522-5. PubMed ID: 18851846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
